Patents
Literature
2 results about "Nicergoline" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Nicergoline (INN, marketed under the trade name Sermion) is an ergot derivative used to treat senile dementia and other disorders with vascular origins. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs. Unlike many other ergolines, such as ergotamine, nicergoline is not associated with fibrosis...
Nicergoline sublingual tablet and its preparation method
PendingCN122097278ANervous disorderPharmaceutical non-active ingredientsOrganic acidPharmaceutical medicine
The present application relates to a sublingual tablet of nicergoline and a preparation method thereof, the sublingual tablet of nicergoline comprising nicergoline and pharmaceutically acceptable excipients; the pharmaceutically acceptable excipients comprise organic acid, diluent, disintegrant and lubricant. In the sublingual tablet of nicergoline, the organic acid as a cosolvent and the combination with nicergoline can increase the cumulative dissolution rate and dissolution rate of nicergoline, and improve the bioavailability and pharmacodynamic persistence of nicergoline. At the same time, the sublingual tablet of nicergoline can avoid liver first-pass effect, and has the advantages of convenient use and no need of water for administration.
Owner:HANGZHOU YIZHENGYUN BIOMEDICAL TECHNOLOGY CO LTD
Nicergoline sublingual tablet and preparation method therefor
PCT designated stageWO2026113988A1Nervous disorderPharmaceutical non-active ingredientsOrganic acidPharmaceutical medicine
Provided are a nicergoline sublingual tablet and a preparation method therefor. The nicergoline sublingual tablet comprises nicergoline and a pharmaceutically acceptable auxiliary material; the pharmaceutically acceptable auxiliary material comprises an organic acid, a diluent, a disintegrant and a lubricant. In the nicergoline sublingual tablet, the organic acid is used as a co-solvent, and the compounding of same with nicergoline can increase the cumulative dissolution rate and dissolution speed of nicergoline, thereby improving the bioavailability and efficacy durability of nicergoline. The nicergoline sublingual tablet can avoid the hepatic first-pass effect, and has the advantages of convenient use and no need to be taken with water.
Owner:HANGZHOU YIZHENGYUN BIOMEDICAL TECHNOLOGY CO LTD